AstraZeneca enters China with Plendil
London | 02 March 2016

AstraZeneca has entered into a licensing agreement with China Medical System (CMS) Holdings for the commercialisation rights in China to its calcium channel blocker, Plendil (felodipine).

Under the terms of the agreement, CMS will pay $310 million to AstraZeneca for the license to sell Plendil in China.

AstraZeneca will retain the global rights to Plendil outside of China and will supply the medicine to CMS.

Plendil achieved product sales of $189 million in 2015.

Mark Mallon, executive vice president at AstraZeneca, said: “This collaboration supports our strategy of working with a local partner to maximise the value from our medicines in China, our second largest market globally.”

Author: Tammy Facey



More IPPro Life Sciences | latest news
AstraZeneca enters China with Plendil
Hogan Lovells boosts capabilities in Japan
Morgan Lewis bags four from K&L Gates
Cobra and CPI enter £1.8 million project
Doctors Without Borders urges lower vaccine prices
IPPro Life Sciences
IPPRO ARCHIVES
BACK ISSUES ONLINE
COMPANY INFO
ABOUT US

THE TEAM


Copyright (C) 2013 Black Knight Media Ltd. All rights reserved. No reproduction without prior authorization